Posts Tagged 'farxiga'

Trouble for Diabetes Drug Makers?

invokana and farxiga mdls to move forwardKnown as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.

Unfortunately, this relatively new class of drugs has already allegedly caused enough harm to warrant FDA action ...

continue reading...

New SGLT2 Inhibitor Joins Troubled Class of Diabetes Drugs

new sglt2 inhibitor set to go to marketAccording to a Nasdaq report, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes drug, Synjardy. Synjardy is the latest in a new line of diabetes medications known as sodium-glucose cotransporter-2 inhibitors, called SGLT2 inhibitors for short.

SGLT2 inhibitors help lower patients’ blood sugar by preventing reabsorption of glucose in the kidneys and eliminating excess sugar through urine. However, SGLT2 ...

continue reading...

FDA: SGLT2 Inhibitors May Lead to Serious Blood Condition

drug safety warning issued for sglt2 inhibitorsThe U.S. Food and Drug Administration (FDA) has issued a Drug Safety Communication warning that the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin may result in ketoacidosis, a serious blood condition in which the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can prove fatal. The SLGT2 inhibitors are marketed under the brand names Invokana, Invokamet, Farxiga, Jardiance, Glyxambi, and Xigduo XR.

SGLT2 ...

continue reading...